Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
Division of Fundamental Health Sciences, School of Nursing and Social Services, Health Sciences University of Hokkaido, Tobetsu, Japan.
Immunol Med. 2022 Jun;45(2):108-118. doi: 10.1080/25785826.2021.1976942. Epub 2021 Sep 19.
Despite the considerable success of cancer immunotherapy with immune checkpoint inhibitors, their nonspecific release of the immunosuppressive mechanism is often associated with immune-related adverse events (irAEs). irAEs significantly disturb patients' quality of life and can even be life-threatening. Therefore, the appropriate management of irAEs is crucial for the development of further reliable cancer immunotherapies. irAEs have the appearance of ordinary autoimmune diseases in one aspect but often have distinct features. Although the detailed pathogenesis of irAEs remains unclear, increasing numbers of studies have provided numerous clues. Here, we review the current knowledge on irAEs, particularly from an immunopathological basis.
尽管免疫检查点抑制剂在癌症免疫治疗方面取得了相当大的成功，但它们对免疫抑制机制的非特异性释放常常与免疫相关不良事件（irAEs）有关。irAEs 严重干扰患者的生活质量，甚至可能危及生命。因此，irAEs 的适当管理对于进一步开发可靠的癌症免疫疗法至关重要。irAEs 在一方面表现出普通自身免疫性疾病的特征，但往往具有独特的特征。尽管 irAEs 的详细发病机制尚不清楚，但越来越多的研究提供了许多线索。在这里，我们回顾了 irAEs 的现有知识，特别是从免疫病理学基础方面。
